Bubble Bubble, Toil and Trouble – or Not?
In the wake of bursting housing and financial bubbles, it is little wonder why there is widespread speculation throughout the venture capital and private equity…
Posted by
Safeguard Insights
Taming Regulatory Reform
Many a CFO has lost more than a night’s sleep contemplating both the intended and unintended consequences of new healthcare regulations. Because of the uncertainty…
Posted by
Life Sciences Trends for 2011: Companion Diagnostics, Reimbursement and Consumerization
Last week, Safeguard Scientifics’ Life Sciences team attended J.P. Morgan’s 29th Annual Healthcare Conference and OneMedForumSF 2011 (video) in San Francisco. Our main takeaway is that…
Posted by
2010 Achievements and 2011 Outlook: Safeguard Scientifics, Capital Markets, Regulatory Compliance and more
Last year around this time, as we headed into 2010 and were making plans for the coming year, we were in the midst of the…
Posted by
Communicating Value and Increasing Transparency
Cash on our balance sheet may be growing with every well-timed exit transaction and positive momentum is driving Safeguard’s stock price upward; however, our IR…
Posted by
Discussing Life Sciences Trends at J.P. Morgan Healthcare Conference and OneMedForum
This week, our life sciences team is heading out to San Francisco to attend J.P. Morgan’s 29th Annual Healthcare Conference, one of the life science…
Posted by
Challenges for Corporate CEOs in 2011
2010 was a trying year for every business. Even with the recent glimmers of economic improvement, 2011 will be no less challenging. I was recently…
Posted by
Capital Available
In this morning’s Wall Street Journal, Justin Lahart wrote an article titled “Companies Cling to Cash.” Justin reports that there is an increasing number of…
Posted by
IPOs: A Financing Event
On the heels of continued IPO activity, there has been a flurry of media coverage — both positive and negative — regarding the companies that…
Posted by
